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Abstract
Background: Burkholderia pseudomallei is a Category B select agent and the cause of melioidosis. Research funding for
vaccine development has largely considered protection within the biothreat context, but the resulting vaccines could be
applicable to populations who are at risk of naturally acquired melioidosis. Here, we discuss target populations for
vaccination, consider the cost-benefit of different vaccination strategies and review potential vaccine candidates.
Methods and Findings: Melioidosis is highly endemic in Thailand and northern Australia, where a biodefense vaccine might
be adopted for public health purposes. A cost-effectiveness analysis model was developed, which showed that a vaccine
could be a cost-effective intervention in Thailand, particularly if used in high-risk populations such as diabetics. Cost-
effectiveness was observed in a model in which only partial immunity was assumed. The review systematically summarized
all melioidosis vaccine candidates and studies in animal models that had evaluated their protectiveness. Possible candidates
included live attenuated, whole cell killed, sub-unit, plasmid DNA and dendritic cell vaccines. Live attenuated vaccines were
not considered favorably because of possible reversion to virulence and hypothetical risk of latent infection, while the other
candidates need further development and evaluation. Melioidosis is acquired by skin inoculation, inhalation and ingestion,
but routes of animal inoculation in most published studies to date do not reflect all of this. We found a lack of studies using
diabetic models, which will be central to any evaluation of a melioidosis vaccine for natural infection since diabetes is the
most important risk factor.
Conclusion: Vaccines could represent one strand of a public health initiative to reduce the global incidence of melioidosis.
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Introduction
Burkholderia pseudomallei has been the subject of intensive research
over the past decade following its classification by the CDC as a
category B select agent [1]. The potential for this bacterium to
cause clinical disease (melioidosis) after inhalation, coupled with
the low infective dose by this route and the ease with which the
bacterium can be obtained and cultured are characteristics of a
pathogen that might be used for malevolent purposes. Much
recent research on B. pseudomallei has focused on identifying ways
in which the bacterium causes disease with a view to devising
biodefense vaccines, and significant progress has been made in
demonstrating the feasibility of immunization against melioidosis
in animal models [2].
Unlike many of the other biothreat organisms, B. pseudomallei is
also an important cause of naturally acquired human infection.
This organism is present in the environment across much of SE
Asia and N Australia, and infection results from bacterial
inoculation, inhalation or ingestion. Most cases are reported from
NE Thailand and N Australia, although melioidosis has been
increasingly reported in the Indian subcontinent, China, the
Middle East, Africa and South America [3,4]. In NE Thailand,
melioidosis is the third most common cause of death from
infectious diseases, exceeded only by HIV and tuberculosis [5]. In
Darwin, N Australia, melioidosis is the commonest cause of fatal
community-acquired septicemic pneumonia [6]. B. pseudomallei is
inherently resistant to many antibiotics, including first, second and
third generation cephalosporins, aminoglycosides, penicillins and
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associated mortality rate is 43% in NE Thailand [5] and 14% in N
Australia [8]. Against this background, there may be an
opportunity to use vaccines devised for biodefense purposes for
the control of naturally acquired infection. Here, we discuss target
populations for vaccination, consider the cost-benefit of different
vaccination strategies, and review potential vaccine candidates.
Methods
Cost-effectiveness analysis of vaccination against
melioidosis
We considered the cost-effectiveness of vaccination against
melioidosis in NE Thailand, though our models could be applied
to other areas of the world where the disease is endemic. We used
a Markov model to estimate cost and quality adjusted life years
(QALYs) as patients transition between different health states
(Figure 1). Table 1 lists the values used for the variables in the
model. Our analysis considered the potential benefits of a
melioidosis vaccine to reduce (i) disease incidence, and (ii)
mortality with varying degrees of protective efficacy for each of
these actions. The protective efficacy (PE) and protective duration
(PD) of the vaccine were assumed to be homogenous for all routes
of disease acquisition. Health benefits were assessed in terms of
QALYs gained [9]. The incremental cost-effectiveness ratio
(ICER) for a QALY gained was compared with the GDP per
capita, which is a proxy measure for the assumed willingness to
pay for a QALY gained [10,11]. We assumed that Thailand was
willing to pay (WTP) $3,000 for an additional QALY gained which
approximates the Thai GDP/capita [10]. Given the uncertainties
surrounding the PE and PD of a potential vaccine together with its
costs and disease incidence in different target populations, results
are presented for a broad but plausible range of estimates for each
of these parameters. The cost-effectiveness analysis was carried out
using Treeage Pro (TreeAge Software Inc., Williamstown, MA,
USA).
Search strategy and selection criteria
We performed a PubMed (MEDLINE) search of the literature
using the keywords ‘‘pseudomallei’’, ‘‘vaccine’’, ‘‘immunity’’ and
‘‘protect’’, and reviewed the available references published
between January 1911 and Oct 2011. The inclusion criterion
used was publication of the vaccine efficacy in humans or in
animal models of melioidosis. Initially, titles and abstracts were
screened. Articles identified as possibly relevant were reviewed as
full text. The reference lists of included articles were assessed for
further relevant publications. To inform discussion on the
development of vaccine candidates, the animal models used for
the vaccine trials were also reviewed.
Results and Discussion
Target population for a melioidosis vaccine
Countries that might consider using a biodefense vaccine for the
control of endemic melioidosis include Thailand and Australia,
where the most reliable estimates of the incidence of melioidosis
are available [4]. The annual incidence of human melioidosis in
NE Thailand and the Top End of N Australia are currently 21.0
and 19.6 per 100,000 population, respectively [5,12]. However,
incidence rates are not uniform within the population, with certain
populations at particularly high risk, including those with diabetes
mellitus, chronic lung disease or chronic kidney failure [5,12]. For
example, the annual incidence rates in diabetics have been
estimated to be 145.7 and 260.4 per 100,000 population in NE
Thailand and N Australia, respectively [5,12]. The annual
incidence rates in patients in N Australia with chronic lung
disease or chronic kidney disease have been estimated to be 102.0
and 119.6 per 100,000 population, respectively [12]. People older
than 35 years are also at higher risk (26.2 versus 4.3 per 100,000
population per year for over or under 35 years of age, respectively)
[5].
High-risk groups could be considered as primary targets for
melioidosis vaccine trials. One disadvantage may be that
generating protective immunity in individuals with such underly-
ing diseases may be difficult to achieve. Furthermore, limiting
vaccination to people with diabetes, chronic lung disease or
chronic kidney failure would only capture around 60% to 70% of
all melioidosis cases [5,12]. In addition, around 15% of patients
presenting with melioidosis have previously undiagnosed diabetes.
An alternative target group would be all people over 35 years of
age residing in an area where melioidosis is known to occur.
Vaccinating this much larger group would be predicted to be less
cost-effective, but would capture the majority of possible
melioidosis patients.
Routes of B. pseudomallei infection and implications for
vaccine development
The commonest routes of B. pseudomallei infection are thought to
be inoculation, inhalation and ingestion [13]. The prevailing
assumption is that most naturally occurring disease results from
percutaneous inoculation [13]. This is largely based on the
observation that people at high risk such as agricultural workers do
not wear protective clothing, work with bare feet, and suffer
repeated minor injuries. In addition, disease incidence increases
during the rainy season when rice farmers have regular and
prolonged contact with contaminated soil and water [8,14].
Although entirely feasible, this association is not supported by
published evidence. A retrospective study performed in N
Australia found that less than one quarter of people presenting
with melioidosis recalled an injury in the preceding weeks [6], and
a case-control study conducted in the same setting found that
exposure to soil was not associated with melioidosis [15].
Inhalation of B. pseudomallei suspended in aerosols generated from
the environment was considered to be an important mechanism
for infection in US combatants during the conflict with Vietnam,
particularly in helicopter crewmen [16]. Published evidence for
inhalation as a route of infection in the general population is
Author Summary
The designation of Burkholderia pseudomallei as a category
B select agent has resulted in considerable research
funding to develop a protective vaccine. This bacterium
also causes a naturally occurring disease (melioidosis), an
important cause of death in many countries including
Thailand and Australia. In this study, we explored whether
a vaccine could be used to provide protection from
melioidosis. An economic evaluation based on its use in
Thailand indicated that a vaccine could be a cost-effective
intervention if used in high-risk populations such as
diabetics and those with chronic kidney or lung disease.
A literature search of vaccine studies in animal models
identified the current candidates, but noted that models
failed to take account of the common routes of infection in
natural melioidosis and major risk factors for infection,
primarily diabetes. This review highlights important areas
for future research if biodefence-driven vaccines are to
play a role in reducing the global incidence of melioidosis.
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towards a higher frequency of pneumonia and severe disease
during the rainy season or following heavy monsoon rains and
winds [17,18]. There is also evidence for ingestion as an important
route of B. pseudomallei infection. Several clusters of melioidosis
cases have been reported from Australia in which a strain of B.
pseudomallei isolated from a common water source was a genetic
match for the strain causing disease in the cluster [19,20]. The
probability of this occurring by chance is small since B. pseudomallei
is genetically extremely diverse [21]. B. pseudomallei has also been
isolated from public water supplies in 11 locations in the Northern
Territory of Australia, genotyped and implicated as a source of
infection in 6 locations [22]. In addition, acute suppurative
parotitis, which is common in pediatric melioidosis patients in NE
Thailand, is presumed to result from direct entry of organisms
present in the mouth. In the absence of information on the relative
importance of each route of infection it is clear that a melioidosis
vaccine for public health purposes should protect against oral,
inhalational and percutaneous challenges.
Cost-effectiveness of vaccination against melioidosis
The model used was based on the effect of a full course of
vaccine, which could be either a single inoculation or multiple
inoculations. Two target populations were considered: (i) all
individuals older than 35 years of age; or (ii) a high-risk group with
diabetes mellitus, chronic lung disease or chronic kidney failure.
We considered situations where protective efficacy (PE) of a
vaccine course ranged from 0 to 100%, protective duration (PD)
ranged from 1 to 15 years, and the cost of a full vaccine course
ranged from $1t o$50 (Table 1). PE was assumed to be
homogenous across the target population.
Figure 2 shows some situations where a vaccine would be
predicted to be cost-effective. With a PD of one year, a vaccine
was only cost-effective in the group with major risk factors
(estimated annual incidence of 150 per 100,000 persons) and
provided that the PE was over 50% and cost was less than $2. If
the PD was 3 years, a vaccine at the same price and PE would be
cost effective in all adults with an average incidence of 25 per
100,000. If the PD was 3 years, PE was 100%, and only high risk
group were targeted, the full vaccine course could rise to $10, and
still represent a cost-effective intervention. A vaccine course that
reduced both incidence rate and mortality of melioidosis by 50%
with a PD of at least 10 years could cost up to $10 in the general
adult population and over $ 25 in diabetics and maintain its cost-
effectiveness.
The potential number of deaths averted and costs associated
with different vaccine target populations in NE Thailand assuming
that the PE of a vaccine was 50% are shown in Table 2. The
estimates are for a single cycle, and so both the costs and potential
number of deaths averted would repeat themselves at the end of
the duration of PE.
Vaccine candidates
We identified 29 studies that examined the following vaccine
types: live attenuated (n=11), whole cell killed (n=5), subunit
(n=9), plasmid DNA (n=2) and dendritic cell (n=2) (Figure 3).
All of the vaccine candidates were evaluated in mouse models, but
the B. pseudomallei strains used, doses and routes of lethal challenge
were highly variable (Table S1). Sterile immunity was rarely
reported. Vaccines being developed for biodefence purposes would
need to protect primarily against an inhalation challenge. The
available experimental evidence indicated that this might be
challenging, since the protective efficacy of tested vaccines was
greater against intraperitoneal challenge compared with inhalation
or intranasal challenge (Table S1). Studies of protection following
an ingestion challenge have not been reported.
Live attenuated vaccines
A wide range of attenuated B. pseudomallei mutants have been
reported, and immunization of mice with some of these has
resulted in the induction of protective immunity [23,24,25,26,27,
28,29,30,31,32,33]. Live attenuated mutants of B. pseudomallei have
been shown to be capable of inducing protection against either an
injected or an intranasal challenge, but protection was strongly
dependent on immunization by the same route as challenge (Table
S1). A potential advantage of a live attenuated vaccine is the likely
ability to induce long-term protection against disease [34]. For
example, the live attenuated tularemia vaccine induces cell-
mediated responses which persist for at least 3 decades [35] and
immunity after vaccination with vaccinia virus persists for decades
[36] and possibly for the lifetime of the individual [37]. A live
Table 1. Data used in the cost-effectiveness model.
Inputs Value Sources
Incidence of melioidosis in NE Thailand [5]
- In the general population 21.0 per 100,000 person yrs
- In people older than 35 years old 26.2 per 100,000 person yrs
- In people with diabetes 145.7 per 100,000 person yrs
Mortality rate of melioidosis in NE Thailand 43% [5]
Population of NE Thailand 21.4 million [5]
Willingness to pay for a quality-adjusted life year (QALY) gained in Thailand $3,000 [10]
Parameters Range of parameters
Vaccine efficacy
- Reduction in incidence of melioiodosis 0 to 100% reduction
- Reduction in mortality from melioidosis 0 to 100% reduction
Protective duration 1 to 15 years
Cost of vaccine $1t o$50
doi:10.1371/journal.pntd.0001488.t001
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protection is likely to be highly cost-effective. However, it may
prove difficult to license a live attenuated mutant for use in
humans in endemic areas. This bacterium has the potential to
cause a potentially life-threatening disease that is difficult to treat,
and one would need confidence that reversion of an attenuated
mutant to virulence was not possible. In addition, there is a
concern that an attenuated mutant might become established as a
latent infection. This is found on observation that B. pseudomallei
can survive for extend periods in the human host, the longest
reported duration of naturally acquired latency prior to clinical
symptoms being 62 years [38]. Concerns over the use of a live
attenuated meliodosis vaccine are heightened by the knowledge
that most naturally occurring cases of disease occur in individuals
who are likely to have some degree of immune dysfunction.
Inactivated whole cell vaccines
Inactivated vaccines are used widely to protect against viral
infections, but there are few examples of inactivated bacterial
vaccines in current use. Inactivated vaccines are relatively easy and
cheap to produce and are capable of inducing protective immunity
that persists for several years. For example, protective immunity
after immunization with inactivated Salmonella enterica serovar
Typhi is reported to persist for at least 30 months [39,40]. A
potential advantage of killed cell vaccines is their ability to present
a wide range of antigens to the immune system. This might be
important when considering the genetic and immunological
diversity of B. pseudomallei. Kill B. pseudomallei has resulted in the
induction of protective immunity [41,42,43]. Killed B. thailandensis,
a closely related but avirulent organism, was able to induce
comparable protection against killed B. pseudomallei [44], and
intranasal inoculation of killed B. pseudomallei plus adjuvant CLDC
(cationic lipid-DNA complex) gave protection from lethal
pulmonary challenge [45]. The main disadvantage of killed cell
vaccines is the potential for short-term but undesirable side effects.
In other killed cell vaccines, these side effects are largely attributed
to the pyrogenic effects of the lipid A portion of lipopolysaccharide
(LPS) [46]. However, B. pseudomallei LPS is reported to be at least
ten times less potent in eliciting nitric oxide and tumor necrosis
factor a from macrophages than LPS from Escherichia coli or
Salmonella enterica [47,48]. In addition, B. pseudomallei LPS is less
potent than enterobacterial LPS in the induction of pyrogenic
activity in rabbits and lethality in galactosamine-sensitized mice
[49]. Thus some of the concerns over the use of killed cell vaccines
for melioidosis may not be justified, although detailed studies with
a killed cell vaccine would be required to confirm the safety and
lack of reactogenicity of such a preparation in animal models and
humans.
Sub-unit vaccines
Sub-unit vaccines incorporate specific molecules derived from a
microorganism and are the aspiration of most vaccine research
programmes. The potential advantages of these vaccines lie with
their increased safety and ability to evoke immune responses only
to the protective antigen rather than to the entire microorganism.
The duration of protection elicited after immunization with a sub-
unit vaccine may differ markedly from vaccine to vaccine and
between different population. For example, polysaccharide
vaccines often elicit short-lived responses, especially in infants
[50]. However, many protein-based vaccines, such as tetanus
toxoid and hepatitis B vaccine, can elicit protective immunity
which persists for at least a decade [51,52].
A range of proteins and polysaccharides have been identified that
induce different degrees of protection against an intraperitoneal B.
pseudomallei challenge in mice [53,54,55,56,57,58,59,60,61]. Of
these, the most protective appear to be LPS, capsular polysaccha-
ride (CPS), LolC protein (an inner membrane protein which forms
part of a lipoprotein export system), an outer membrane protein
Omp85, and Hcp2 (integral surface-associated component of
T6SS). A minority of B. pseudomallei strains produce LPS with an
immunologically distinct O-antigen [62], raising the possibility that
LPS may not induce protective immunity against all strains. There
are no reports of the ability of these individual sub-units to induce
significant protection against an inhalation challenge, which would
be essential for a biodefense vaccine. However, immunization of
mice with outer membrane vesicles, which are likely to contain a
combination of sub-units, can provide protection against a low-level
(5 LD50 doses) inhalation challenge [61]. There is accumulating
evidence, therefore, that subunit vaccines devised for biodefence use
may be suitable for use in populations in melioidosis endemic areas.
Naked DNA and dendritic cell vaccines
There are two reports on the protection afforded by immunisa-
tionwith DNAvaccinesencoding the B.pseudomallei flagellar subunit
gene, fliC [63,64]. These showed that immunization of mice with
these constructs provided modest levels of protection. However, in
general naked DNA vaccines against infectious diseases have been
weakly immunogenic in humans even though they have promoted
vigorousandeffective immuneresponsesinmice[65].Toovercome
these limitations prime-boost strategies have often been adopted to
allow the development of protective immunity [65]. Two studies
have been published on dendritic cells pulsed with heat-killed whole
cell B. pseudomallei [66,67]. Dendritic cell vaccines have been
increasingly evaluated in clinical trials for cancer [68], and there is
still a need to undertake more proof of principle studies evaluating
their utility as vaccines for infectious diseases [69].
Table 2. Cost and deaths averted if a melioidosis vaccine
a was implemented in NE Thailand.
Target group Population in NE Thailand Protective duration Deaths prevented Cost (single cycle)
people older than 35 years old ,9.5 million 1 year 612 $48 million
3 years 1838
10 years 6127
people with diabetes ,250,000 1 year 121 $1.3 million
3 years 363
10 years 1209
aThe melioidosis vaccine was assumed to have 50% protective efficacy (reduction of disease incidence by 50% and reduction of mortality rate in diseased patients by
50%) and cost 5 dollars.
doi:10.1371/journal.pntd.0001488.t002
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Suitable animal models of infection will be central to any
melioidosis vaccine development programme. A myriad of
different infection models are available, reflecting the different
forms of disease in humans. Acute disease occurs in some mouse
strains (e.g. BALB/c), and in hamsters with death typically
occurring within 7 days of challenge by the intraperitoneal route.
Challenge of BALB/c mice by the inhalation or intranasal route
results in hyperacute disease, with death within a few days.
C57BL/6 mice are typically 10
4-fold more resistant to disease than
Figure 1. The Markov model used to assess costs and health gains for a melioidosis vaccine. M denotes a Markov node where individuals
can transition into the subsequent states in each monthly cycle. In each cycle a susceptible patient can be infected and develop a melioidosis
episode, from which they can recover and return to the susceptible state in the next cycle, or die. Patients can also die from natural causes according
to their age specific mortality rates.
doi:10.1371/journal.pntd.0001488.g001
Figure 2. Cost-effectiveness of melioidosis vaccines as determined by incidence, cost, protective efficacy and protective duration. It
was assumed that policy makers in Thailand were willing to pay $3,000 for an additional QALY gained. Areas in blue indicate where the vaccine is
considered cost-effective in the Thai context. The protective efficacy (PE) and protective duration (PD) of the vaccine were considered as
homogenous for all routes of disease acquisition. Percentage reduction of PE in this figure was considered as a combination of reduction in both
disease incidence and mortality rate.
doi:10.1371/journal.pntd.0001488.g002
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of the disease which shows similarities with chronic melioidosis in
humans [70]. Chronic melioidosis can also be observed in BALB/
c mice after low-dose exposure [71,72]. There are two reports of
disease after enteral challenge of mice with B. pseudomallei [73], but
there is a clear need for the further development of animal models
of disease following ingestion of the bacteria.
Diabetic mouse models of melioidosis have not been well
described [74,75], but are highly desirable for evaluating vaccines
for natural infection. Mice can be made diabetic for extended
periods of time by dosing with streptozotocin, and dendritic cells
and macrophages isolated from streptozotocin-induced diabetic
mice have altered abilities to ingest and kill B. pseudomallei [76].
Young diabetic rats were found to be susceptible to B. pseudomallei,
but not adult diabetic rats [74,75], which is not comparable to the
natural situation in humans in which diabetics with melioidosis are
predominantly adults.
Efficacy studies in non-human primates are also likely to be
required for approval of melioidosis vaccine in human clinical
trials. Although mouse models may be useful to screen vaccine
candidates, the patterns of disease and immune responses are often
different from those seen in human. A range of different non-
human primate infection models including marmoset and
macaque are currently being developed, but there are currently
no reported data on the suitability of these models for testing
vaccine candidates.
The form of the disease may also be dependent on the infecting
strain. B. pseudomallei is a genetically diverse genus, and there are
significant differences in the virulence of different strains of B.
pseudomallei, at least in BALB/c mice. There is some evidence of
genetic variation in strains from different continents, suggesting
that it will be important to test vaccines with strains typical of those
encountered by the target population. The finding that some
strains produce an atypical and immunologically distinct O-
antigen means that it may be desirable to test these strains in
efficacy studies. However, the low frequency with which naturally
occurring disease caused by these strains is encountered also
indicates that such testing could be relatively limited. It is of
undoubted importance, however, to identify a panel of B.
pseudomallei isolates that are representative of the genetic diversity
of the bacterium in the range of countries in which the vaccine will
be used. Vaccine efficacy should then be evaluated using this test
panel with the same standard dosages and multiple routes of
inoculation.
Figure 3. Study flow diagram.
doi:10.1371/journal.pntd.0001488.g003
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We have demonstrated that within a plausible range of
estimates for cost and efficacy, it is possible that a vaccine would
be cost-effective for the prevention of naturally acquired
melioidosis. In Thailand, a vaccine is more likely to be a cost-
effective intervention if used in high-risk populations such as
diabetics and possibly in other at-risk groups such as those working
in rice fields. In countries with a higher GDP, it might be cost
effective to immunize the entire population in endemic areas as
well as tourists or military personnel deploying to melioidosis
endemic areas. The finding that a range of candidate vaccines
achieved partial protection against disease in mice suggests
potential for human use. Reduction in disease severity alone
would be predicted to improve outcome in view of the high
mortality rate and the fact that half of all in-patient deaths in
Thailand occur within the first 48 hours as a result of septic shock.
Additional research is required to investigate the potential
synergies between vaccination, early antimicrobial treatment and
improved care of sepsis in resource-restricted settings. Further
studies are also required to determine whether immunization with
the best vaccine candidates protects against multiple routes of
disease acquisition, is effective in diabetic patients, and not
accompanied by unacceptable side effects.
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